AstraZeneca Rövid összefoglaló Approximately 39 million people of adults aged are living with Diabetes in MENA region inEgypt is number 8 in the top 10 countries in number of adults with Diabetes 8.
Metformin is used as 1st line oral anti-diabetic drug in most cases. Sulfonylureas SU are used as frequent first add-on after failure of metformin monotherapy. Sodium Glucose Co-transporter 2 SGLT2 inhibitors are a newer class of therapy which has a lower incidence of hypoglycemia and in addition helps in weight and BP reduction.
It is not yet widely used for various reasons including lack of wide clinical experience in Egyptian patients and safety concerns particularly related to infections and some rare Diabetic Ketoacidosis DKA. Also, usage of SGLT2 inhibitors is limited in the early stage of diabetes as they are usually preferred as 3rd or 4th add-on therapy. The existing dapagliflozin phase-3 clinical trial program on SGLT2 inhibitors didn't include subjects from Egypt.
There is no study available which evaluates the effect of dapagliflozin in real world scenario in Egypt. Key opinion leaders in diabetes in Egypt have also identified the need for study on Egyptian subjects to observe the usage pattern and effect of dapagliflozin, a SGLT2 inhibitor, in this specific real world setting.
Therefore, there is a need for data on real world setting across Egypt. With this aim in mind, the present study has been planned. Átfogó állapot.